Anti-CD3 monoclonal antibodies: A new step towards therapy in new-onset type 1 diabetes;Les anticorps monoclonaux anti-CD3: Une première étape vers un traitement du diabète insulino-dépendant d'origine auto-immune

Medecine/Sciences

Volumn 22, Issue 1, 2006, Pages 5-6

  Chatenoud, Lucienne ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN; INSULIN; MONOCLONAL ANTIBODY CD3; TRANSFORMING GROWTH FACTOR BETA;

AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; GLUCOSURIA; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMMUNOLOGICAL TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; NEPHROTOXICITY; NONHUMAN; NOTE; PANCREAS ISLET BETA CELL; TREATMENT OUTCOME;

EID: 31144472643     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/20062215     Document Type: Note

References (10)

1. Bach JF, Chatenoud L. Tolerance to islet autoantigens in type 1 diabetes. Ann Rev Immunol 2001; 19: 131-61.
2. Feutren G, Papoz L, Assan R, et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 1986; 2: 119-24.
3. The Canadian-European Randomized Control Trial Group. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 year of cyclosporin treatment with enhanced insulin secretion. Diabetes 1988; 37: 1574-82.
4. Chatenoud L, Thervet E, Primo J, et al. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 1994; 91: 123-7.
5. Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997; 158: 2947-54.
6. Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol 2003; 3: 123-32.
7. Belghith M, Bluestone JA, Barriot S, et al. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003; 9: 1202-8.
8. Alegre ML, Peterson LJ, Xu D, et al. A non-activating humanized anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 1994; 57: 1537-43.
9. Bolt S, Routledge E, Lloyd I, et al. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 1993; 23: 403-11.
10. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352: 2598-608.